{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T21:59:13Z","timestamp":1790891953415,"version":"4.1.0"},"reference-count":149,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,19]],"date-time":"2022-12-19T00:00:00Z","timestamp":1671408000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.ejca.2022.11.030","type":"journal-article","created":{"date-parts":[[2022,12,10]],"date-time":"2022-12-10T11:16:15Z","timestamp":1670670975000},"page":"102-118","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["AGIHO guideline on evidence-based management of COVID-19 in cancer patients: 2022 update on vaccination, pharmacological prophylaxis and therapy in light of the omicron variants"],"prefix":"10.1016","volume":"181","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9615-2564","authenticated-orcid":false,"given":"Nicola","family":"Giesen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Busch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1892-5098","authenticated-orcid":false,"given":"Enrico","family":"Schalk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gernot","family":"Beutel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria M.","family":"R\u00fcthrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Hentrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd","family":"Hertenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans H.","family":"Hirsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meinolf","family":"Karthaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5972-0967","authenticated-orcid":false,"given":"Yascha","family":"Khodamoradi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Koehler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Kr\u00fcger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8738-5884","authenticated-orcid":false,"given":"Michael","family":"Koldehoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Krause","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sibylle C.","family":"Mellinghoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olaf","family":"Penack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Sandherr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7488-4791","authenticated-orcid":false,"given":"Ruth","family":"Seggewiss-Bernhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karsten","family":"Spiekermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2457-6437","authenticated-orcid":false,"given":"Rosanne","family":"Sprute","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jannik","family":"Stemler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Weissinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"W\u00f6rmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Heinrich","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9599-3137","authenticated-orcid":false,"given":"Oliver A.","family":"Cornely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina T.","family":"Rieger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"von Lilienfeld-Toal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"18","key":"10.1016\/j.ejca.2022.11.030_bib1","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1056\/NEJMoa2002032","article-title":"Clinical characteristics of coronavirus disease 2019 in China","volume":"382","author":"Guan","year":"2020","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.ejca.2022.11.030_bib2","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa2001017","article-title":"A novel coronavirus from patients with pneumonia in China, 2019","volume":"382","author":"Zhu","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ejca.2022.11.030_bib3","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1186\/s13045-021-01177-0","article-title":"COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA)","volume":"14","author":"Pagano","year":"2021","journal-title":"J Hematol Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2022.11.030_bib4","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s00277-020-04328-4","article-title":"COVID-19 in cancer patients: clinical characteristics and outcome-an analysis of the LEOSS registry","volume":"100","author":"Ruthrich","year":"2021","journal-title":"Ann Hematol"},{"issue":"10","key":"10.1016\/j.ejca.2022.11.030_bib5","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/S1470-2045(20)30442-3","article-title":"COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study","volume":"21","author":"Lee","year":"2020","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2022.11.030_bib6","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1001\/jamaoncol.2021.6199","article-title":"Time-dependent COVID-19 mortality in patients with cancer: an updated analysis of the onCovid registry","volume":"8","author":"OnCovid Study","year":"2022","journal-title":"JAMA Oncol"},{"issue":"10","key":"10.1016\/j.ejca.2022.11.030_bib7","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1182\/blood.2021014124","article-title":"COVID-19 in vaccinated adult patients with hematological malignancies: preliminary results from EPICOVIDEHA","volume":"139","author":"Pagano","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2022.11.030_bib8","unstructured":"WHO. World Health Organization Coronavirus disease (COVID-19) situation reports [Available from: https:\/\/www.who.int\/emergencies\/diseases\/novel-coronavirus-2019\/situation-reports."},{"issue":"14","key":"10.1016\/j.ejca.2022.11.030_bib9","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1056\/NEJMoa2119658","article-title":"Population immunity and COVID-19 severity with omicron variant in South Africa","volume":"386","author":"Madhi","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2022.11.030_bib10","article-title":"COVID-19: hospital admission 50-70% less likely with omicron than delta, but transmission a major concern","volume":"375","author":"Mahase","year":"2021","journal-title":"BMJ"},{"issue":"7902","key":"10.1016\/j.ejca.2022.11.030_bib11","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41586-022-04411-y","article-title":"Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa","volume":"603","author":"Viana","year":"2022","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.ejca.2022.11.030_bib12","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/S1470-2045(22)00273-X","article-title":"Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, onCovid registry study","volume":"23","author":"Pinato","year":"2022","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2022.11.030_bib13","first-page":"100335","article-title":"Coronavirus disease 2019 outcomes, patient vaccination status, and cancer-related delays during the omicron wave: a brief report from the TERAVOLT analysis","volume":"3","author":"Bestvina","year":"2022","journal-title":"JTO Clin Res Rep"},{"issue":"27","key":"10.1016\/j.ejca.2022.11.030_bib14","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.ejca.2022.11.030_bib15","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1056\/NEJMoa2107659","article-title":"Safety and efficacy of NVX-CoV2373 covid-19 vaccine","volume":"385","author":"Heath","year":"2021","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ejca.2022.11.030_bib16","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.ejca.2022.11.030_bib17","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1056\/NEJMoa2101544","article-title":"Safety and efficacy of single-dose Ad26.COV2.S vaccine against covid-19","volume":"384","author":"Sadoff","year":"2021","journal-title":"N Engl J Med"},{"issue":"10269","key":"10.1016\/j.ejca.2022.11.030_bib18","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"issue":"23","key":"10.1016\/j.ejca.2022.11.030_bib19","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1056\/NEJMoa2116620","article-title":"Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for prevention of COVID-19","volume":"386","author":"Levin","year":"2022","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.ejca.2022.11.030_bib20","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1056\/NEJMoa2109682","article-title":"Subcutaneous REGEN-COV antibody combination to prevent covid-19","volume":"385","author":"O'Brien","year":"2021","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.ejca.2022.11.030_bib21","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.1056\/NEJMoa2108163","article-title":"REGEN-COV antibody combination and outcomes in outpatients with COVID-19","volume":"385","author":"Weinreich","year":"2021","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.ejca.2022.11.030_bib22","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1056\/NEJMoa2107934","article-title":"Early treatment for COVID-19 with SARS-CoV-2 neutralizing antibody sotrovimab","volume":"385","author":"Gupta","year":"2021","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.ejca.2022.11.030_bib23","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJMoa2102685","article-title":"Bamlanivimab plus etesevimab in mild or moderate COVID-19","volume":"385","author":"Dougan","year":"2021","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ejca.2022.11.030_bib24","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1056\/NEJMoa2116044","article-title":"Molnupiravir for oral treatment of COVID-19 in nonhospitalized patients","volume":"386","author":"Jayk Bernal","year":"2022","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.ejca.2022.11.030_bib25","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1056\/NEJMoa2118542","article-title":"Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19","volume":"386","author":"Hammond","year":"2022","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ejca.2022.11.030_bib26","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1056\/NEJMoa2116846","article-title":"Early remdesivir to prevent progression to severe COVID-19 in outpatients","volume":"386","author":"Gottlieb","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2022.11.030_bib27","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.ejca.2021.10.014","article-title":"Immunogenicity and risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection after Coronavirus Disease 2019 (COVID-19) vaccination in patients with cancer: a systematic review and meta-analysis","volume":"160","author":"Becerril-Gaitan","year":"2022","journal-title":"Eur J Cancer"},{"issue":"8","key":"10.1016\/j.ejca.2022.11.030_bib28","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.annonc.2021.04.019","article-title":"Impaired immunogenicity of BNT162b2 anti-SARS-CoV-2 vaccine in patients treated for solid tumors","volume":"32","author":"Barriere","year":"2021","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2022.11.030_bib29","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1001\/jamaoncol.2021.5437","article-title":"Humoral immune response in hematooncological patients and health care workers who received SARS-CoV-2 vaccinations","volume":"8","author":"Mair","year":"2022","journal-title":"JAMA Oncol"},{"issue":"12","key":"10.1016\/j.ejca.2022.11.030_bib30","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.1038\/s41418-021-00817-9","article-title":"Prolonged SARS-CoV-2 RNA virus shedding and lymphopenia are hallmarks of COVID-19 in cancer patients with poor prognosis","volume":"28","author":"Goubet","year":"2021","journal-title":"Cell Death Differ"},{"issue":"3","key":"10.1016\/j.ejca.2022.11.030_bib31","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/bjh.17704","article-title":"COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies","volume":"195","author":"Passamonti","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ejca.2022.11.030_bib32","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ejca.2020.09.009","article-title":"Evidence-based management of COVID-19 in cancer patients: guideline by the infectious diseases working party (AGIHO) of the German society for haematology and medical oncology (DGHO)","volume":"140","author":"Giesen","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2022.11.030_bib33","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ejca.2021.01.033","article-title":"2021 update of the AGIHO guideline on evidence-based management of COVID-19 in patients with cancer regarding diagnostics, viral shedding, vaccination and therapy","volume":"147","author":"Giesen","year":"2021","journal-title":"Eur J Cancer"},{"issue":"7","key":"10.1016\/j.ejca.2022.11.030_bib34","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/1469-0691.12041","article-title":"ESCMID\u2217 guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT)","volume":"18","author":"Ullmann","year":"2012","journal-title":"Clin Microbiol Infect"},{"issue":"6","key":"10.1016\/j.ejca.2022.11.030_bib35","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/S1470-2045(22)00202-9","article-title":"Vaccine effectiveness against COVID-19 breakthrough infections in patients with cancer (UKCCEP): a population-based test-negative case-control study","volume":"23","author":"Lee","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2022.11.030_bib36","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ejca.2022.03.013","article-title":"Seropositivity and neutralising antibodies at six months after BNT162b2 vaccination in patients with solid tumours","volume":"168","author":"Margalit","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2022.11.030_bib37","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.ejca.2022.01.019","article-title":"Third dose of SARS-CoV-2 vaccination in hemato-oncological patients and health care workers: immune responses and adverse events - a retrospective cohort study","volume":"165","author":"Mair","year":"2022","journal-title":"Eur J Cancer"},{"issue":"6","key":"10.1016\/j.ejca.2022.11.030_bib38","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/s41571-022-00610-8","article-title":"COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety","volume":"19","author":"Fendler","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ejca.2022.11.030_bib39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2022.06.038","article-title":"COVID-19: third dose booster vaccine effectiveness against breakthrough coronavirus infection, hospitalisations and death in patients with cancer: a population-based study","volume":"175","author":"Lee","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2022.11.030_bib40","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.ejca.2022.01.035","article-title":"Survival and risk of COVID-19 after SARS-COV-2 vaccination in a series of 2391 cancer patients","volume":"165","author":"Heudel","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2022.11.030_bib41","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ejca.2021.12.025","article-title":"Antibody titres before and after a third dose of the SARS-CoV-2 BNT162b2 vaccine in patients with cancer","volume":"163","author":"Debie","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2022.11.030_bib42","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ejca.2022.01.011","article-title":"Rapid decline of humoral response to two doses of BNT162b2 vaccine in patients with solid cancer after six months: the urgent need of the additional dose!","volume":"165","author":"Di Noia","year":"2022","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1016\/j.ejca.2022.11.030_bib43","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/s41408-022-00684-8","article-title":"Effectiveness, immunogenicity, and safety of COVID-19 vaccines for individuals with hematological malignancies: a systematic review","volume":"12","author":"Piechotta","year":"2022","journal-title":"Blood Cancer J"},{"issue":"14","key":"10.1016\/j.ejca.2022.11.030_bib44","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1056\/NEJMoa2208343","article-title":"A bivalent omicron-containing booster vaccine against COVID-19","volume":"387","author":"Chalkias","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2022.11.030_bib45","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ejca.2022.05.029","article-title":"Booster doses of COVID-19 vaccines for patients with haematological and solid cancer: a systematic review and individual patient data meta-analysis","volume":"172","author":"Mai","year":"2022","journal-title":"Eur J Cancer"},{"issue":"12","key":"10.1016\/j.ejca.2022.11.030_bib46","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/S1470-2045(21)00574-X","article-title":"mRNA-1273 COVID-19 vaccination in patients receiving chemotherapy, immunotherapy, or chemoimmunotherapy for solid tumours: a prospective, multicentre, non-inferiority trial","volume":"22","author":"Oosting","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2022.11.030_bib47","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ejca.2021.09.033","article-title":"Regional lymphadenopathy following COVID-19 vaccination: literature review and considerations for patient management in breast cancer care","volume":"159","author":"Garreffa","year":"2021","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.ejca.2022.11.030_bib48","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.ijrobp.2021.02.048","article-title":"COVID-19 vaccine-induced radiation recall phenomenon","volume":"110","author":"Soyfer","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"10.1016\/j.ejca.2022.11.030_bib49","first-page":"e14303","article-title":"Rapid development of clinically symptomatic radiation recall pneumonitis immediately following COVID-19 vaccination","volume":"13","author":"Steber","year":"2021","journal-title":"Cureus"},{"issue":"3","key":"10.1016\/j.ejca.2022.11.030_bib50","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.ijrobp.2021.06.023","article-title":"Radiation recall phenomenon following COVID-19 vaccination","volume":"111","author":"Stewart","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"9","key":"10.1016\/j.ejca.2022.11.030_bib51","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.jtct.2021.06.024","article-title":"Safety and immunogenicity of the BNT162b2 mRNA COVID-19 vaccine in patients after allogeneic HCT or CD19-based CART therapy-A single-center prospective cohort study","volume":"27","author":"Ram","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"1","key":"10.1016\/j.ejca.2022.11.030_bib52","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/ajh.26385","article-title":"SARS-CoV-2-reactive antibody detection after SARS-CoV-2 vaccination in hematopoietic stem cell transplant recipients: prospective survey from the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group (GETH-TC)","volume":"97","author":"Pi\u00f1ana","year":"2022","journal-title":"Am J Hematol"},{"issue":"11","key":"10.1016\/j.ejca.2022.11.030_bib53","doi-asserted-by":"crossref","first-page":"938.e931","DOI":"10.1016\/j.jtct.2021.07.008","article-title":"Safety and tolerability of SARS-CoV2 emergency-use authorized vaccines for allogeneic hematopoietic stem cell transplant recipients","volume":"27","author":"Ali","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.ejca.2022.11.030_bib54","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.ejca.2021.12.011","article-title":"Third dose of anti-SARS-CoV-2 vaccine for patients with cancer: should humoral responses be monitored? A position article","volume":"162","author":"Barriere","year":"2022","journal-title":"Eur J Cancer"},{"issue":"6576","key":"10.1016\/j.ejca.2022.11.030_bib55","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1126\/science.abm3425","article-title":"Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial","volume":"375","author":"Gilbert","year":"2022","journal-title":"Science"},{"issue":"10","key":"10.1016\/j.ejca.2022.11.030_bib56","doi-asserted-by":"crossref","first-page":"2480","DOI":"10.3324\/haematol.2022.280982","article-title":"SARS-CoV-2-specific cellular response following third COVID-19 vaccination in patients with chronic lymphocytic leukemia","volume":"107","author":"Mellinghoff","year":"2022","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.ejca.2022.11.030_bib57","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.ccell.2022.03.010","article-title":"Immune responses following third COVID-19 vaccination are reduced in patients with hematological malignancies compared to patients with solid cancer","volume":"40","author":"Fendler","year":"2022","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.ejca.2022.11.030_bib58","article-title":"Cellular immune response after vaccination in patients with cancer-review on past and present experiences","volume":"10","author":"Ruthrich","year":"2022","journal-title":"Vaccines (Basel)"},{"issue":"5","key":"10.1016\/j.ejca.2022.11.030_bib59","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1056\/NEJMc2207519","article-title":"Efficacy of antibodies and antiviral drugs against omicron BA.2.12.1, BA.4, and BA.5 subvariants","volume":"387","author":"Takashita","year":"2022","journal-title":"N Engl J Med"},{"issue":"7923","key":"10.1016\/j.ejca.2022.11.030_bib60","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/s41586-022-04980-y","article-title":"BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection","volume":"608","author":"Cao","year":"2022","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.ejca.2022.11.030_bib61","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.ccell.2022.05.007","article-title":"Activity of AZD7442 (tixagevimab-cilgavimab) against Omicron SARS-CoV-2 in patients with hematologic malignancies","volume":"40","author":"Stuver","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejca.2022.11.030_bib62","article-title":"Transfusing convalescent plasma as post-exposure prophylaxis against SARS-CoV-2 infection: a double-blinded, phase 2 randomized, controlled trial","author":"Shoham","year":"2022","journal-title":"Clin Infect Dis"},{"issue":"8","key":"10.1016\/j.ejca.2022.11.030_bib63","doi-asserted-by":"crossref","first-page":"e192","DOI":"10.1016\/S1473-3099(20)30483-7","article-title":"Management of C-i. A minimal common outcome measure set for COVID-19 clinical research","volume":"20","author":"WHOWGotC","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ejca.2022.11.030_bib64","article-title":"Repurposed antiviral drugs for COVID-19-interim WHO solidarity trial results","author":"Pan","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ejca.2022.11.030_bib65","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1038\/s41467-021-22446-z","article-title":"Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials","volume":"12","author":"Axfors","year":"2021","journal-title":"Nat Commun"},{"issue":"21","key":"10.1016\/j.ejca.2022.11.030_bib66","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1056\/NEJMoa2019014","article-title":"Hydroxychloroquine with or without azithromycin in mild-to-moderate COVID-19","volume":"383","author":"Cavalcanti","year":"2020","journal-title":"N Engl J Med"},{"issue":"10259","key":"10.1016\/j.ejca.2022.11.030_bib67","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/S0140-6736(20)32013-4","article-title":"Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial","volume":"396","year":"2020","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.ejca.2022.11.030_bib68","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1002\/iid3.502","article-title":"Efficacy and safety of arbidol (umifenovir) in patients with COVID-19: a systematic review and meta-analysis","volume":"9","author":"Amani","year":"2021","journal-title":"Immun Inflamm Dis"},{"issue":"12","key":"10.1016\/j.ejca.2022.11.030_bib69","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1007\/s10096-021-04307-1","article-title":"Effectiveness of favipiravir in COVID-19: a live systematic review","volume":"40","author":"Ozlusen","year":"2021","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"9","key":"10.1016\/j.ejca.2022.11.030_bib70","first-page":"11","article-title":"Ivermectin for prophylaxis and treatment of COVID-19: a systematic review and meta-analysis","author":"Cruciani","year":"2021","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.ejca.2022.11.030_bib71","unstructured":"EMA. Regkirona product information [Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/regkirona-epar-procut-information_en.pdf."},{"key":"10.1016\/j.ejca.2022.11.030_bib72","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-2600(22)00180-1","article-title":"Efficacy and safety of intramuscular administration of tixagevimab-cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial","author":"Montgomery","year":"2022","journal-title":"Lancet Respir Med"},{"issue":"7","key":"10.1016\/j.ejca.2022.11.030_bib73","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMoa2033700","article-title":"Early high-titer plasma therapy to prevent severe COVID-19 in older adults","volume":"384","author":"Libster","year":"2021","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.ejca.2022.11.030_bib74","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1056\/NEJMoa2103784","article-title":"Early convalescent plasma for high-risk outpatients with COVID-19","volume":"385","author":"Korley","year":"2021","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.ejca.2022.11.030_bib75","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1056\/NEJMoa2119657","article-title":"Early outpatient treatment for COVID-19 with convalescent plasma","volume":"386","author":"Sullivan","year":"2022","journal-title":"N Engl J Med"},{"issue":"10359","key":"10.1016\/j.ejca.2022.11.030_bib76","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/S0140-6736(22)01586-0","volume":"400","author":"Wong","year":"2022","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.ejca.2022.11.030_bib77","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1056\/NEJMoa2204919","article-title":"Nirmatrelvir use and severe COVID-19 outcomes during the omicron surge","volume":"387","author":"Arbel","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2022.11.030_bib78","unstructured":"NIH. [Available from: https:\/\/www.covid19treatmentguidelines.nih.gov\/therapies\/antiviral-therapy\/ritonavir-boosted-nirmatrelvir-paxlovid-\/paxlovid-drug-drug-interactions\/."},{"issue":"7","key":"10.1016\/j.ejca.2022.11.030_bib79","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S2213-2600(21)00160-0","article-title":"Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial","volume":"9","author":"Ramakrishnan","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"1","key":"10.1016\/j.ejca.2022.11.030_bib80","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1001\/jamainternmed.2021.6759","article-title":"Efficacy of inhaled ciclesonide for outpatient treatment of adolescents and adults with symptomatic COVID-19: a randomized clinical trial","volume":"182","author":"Clemency","year":"2022","journal-title":"JAMA Intern Med"},{"issue":"10303","key":"10.1016\/j.ejca.2022.11.030_bib81","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S0140-6736(21)01744-X","article-title":"Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial","volume":"398","author":"Yu","year":"2021","journal-title":"Lancet"},{"issue":"22","key":"10.1016\/j.ejca.2022.11.030_bib82","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1001\/jama.2020.22760","article-title":"Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial","volume":"324","author":"Lenze","year":"2020","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.ejca.2022.11.030_bib83","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S2213-2600(21)00222-8","article-title":"Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial","volume":"9","author":"Tardif","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"5","key":"10.1016\/j.ejca.2022.11.030_bib84","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.healun.2020.03.012","article-title":"COVID-19 illness in native and immunosuppressed states: a clinical-therapeutic staging proposal","volume":"39","author":"Siddiqi","year":"2020","journal-title":"J Heart Lung Transplant"},{"issue":"19","key":"10.1016\/j.ejca.2022.11.030_bib85","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the treatment of COVID-19-final report","volume":"383","author":"Beigel","year":"2020","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ejca.2022.11.030_bib86","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2023184","article-title":"Repurposed antiviral drugs for COVID-19-interim WHO solidarity trial results","volume":"384","author":"Pan","year":"2021","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ejca.2022.11.030_bib87","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S1473-3099(21)00485-0","article-title":"Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial","volume":"22","author":"Ader","year":"2022","journal-title":"Lancet Infect Dis"},{"issue":"10339","key":"10.1016\/j.ejca.2022.11.030_bib88","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1016\/S0140-6736(22)00519-0","article-title":"Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses","volume":"399","year":"2022","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ejca.2022.11.030_bib89","doi-asserted-by":"crossref","first-page":"e450","DOI":"10.1093\/cid\/ciab875","article-title":"Remdesivir treatment in hospitalized patients with coronavirus disease 2019 (COVID-19): a comparative analysis of in-hospital all-cause mortality in a large multicenter observational cohort","volume":"75","author":"Mozaffari","year":"2022","journal-title":"Clin Infect Dis"},{"issue":"10","key":"10.1016\/j.ejca.2022.11.030_bib90","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1158\/2159-8290.CD-20-0941","article-title":"Utilization of COVID-19 treatments and clinical outcomes among patients with cancer: a COVID-19 and cancer consortium (CCC19) cohort study","volume":"10","author":"Rivera","year":"2020","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ejca.2022.11.030_bib91","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(22)00507-2","article-title":"Real-world effectiveness of early molnupiravir or nirmatrelvir-ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong's omicron BA.2 wave: a retrospective cohort study","author":"Wong","year":"2022","journal-title":"Lancet Infect Dis"},{"issue":"10325","key":"10.1016\/j.ejca.2022.11.030_bib92","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(22)00163-5","article-title":"Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial","volume":"399","year":"2022","journal-title":"Lancet"},{"issue":"10289","key":"10.1016\/j.ejca.2022.11.030_bib93","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1016\/S0140-6736(21)00897-7","article-title":"Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial","volume":"397","year":"2021","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.ejca.2022.11.030_bib94","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1056\/NEJMoa2031304","article-title":"A randomized trial of convalescent plasma in COVID-19 severe pneumonia","volume":"384","author":"Simonovich","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2022.11.030_bib95","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2021.1799","article-title":"Association of convalescent plasma therapy with survival in patients with hematologic cancers and COVID-19","author":"Thompson","year":"2021","journal-title":"JAMA Oncol"},{"issue":"17","key":"10.1016\/j.ejca.2022.11.030_bib96","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1001\/jama.2021.18178","article-title":"Effect of convalescent plasma on organ support-free days in critically ill patients with COVID-19: a randomized clinical trial","volume":"326","author":"Estcourt","year":"2021","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.ejca.2022.11.030_bib97","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJMoa2021436","article-title":"Dexamethasone in hospitalized patients with COVID-19","volume":"384","author":"Group","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2022.11.030_bib98","article-title":"Baricitinib plus remdesivir for hospitalized adults with COVID-19","author":"Kalil","year":"2020","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ejca.2022.11.030_bib99","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1056\/NEJMoa2101643","article-title":"Tofacitinib in patients hospitalized with COVID-19 pneumonia","volume":"385","author":"Guimaraes","year":"2021","journal-title":"N Engl J Med"},{"issue":"10285","key":"10.1016\/j.ejca.2022.11.030_bib100","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/S0140-6736(21)00676-0","article-title":"Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial","volume":"397","year":"2021","journal-title":"Lancet"},{"issue":"16","key":"10.1016\/j.ejca.2022.11.030_bib101","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1056\/NEJMoa2100433","article-title":"Interleukin-6 receptor antagonists in critically ill patients with COVID-19","volume":"384","author":"Investigators","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2022.11.030_bib102","article-title":"Effectiveness of tocilizumab, sarilumab, and anakinra for critically ill patients with COVID-19 the REMAP-CAP COVID-19 immune modulation therapy domain randomized clinical trial","author":"Derde","year":"2021","journal-title":"medRxiv"},{"issue":"10","key":"10.1016\/j.ejca.2022.11.030_bib103","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1038\/s41591-021-01499-z","article-title":"Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial","volume":"27","author":"Kyriazopoulou","year":"2021","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.ejca.2022.11.030_bib104","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S2213-2600(20)30556-7","article-title":"Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial","volume":"9","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"9","key":"10.1016\/j.ejca.2022.11.030_bib105","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa2031994","article-title":"Baricitinib plus remdesivir for hospitalized adults with COVID-19","volume":"384","author":"Kalil","year":"2021","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.ejca.2022.11.030_bib106","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/S2213-2600(21)00331-3","article-title":"Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial","volume":"9","author":"Marconi","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"9","key":"10.1016\/j.ejca.2022.11.030_bib107","first-page":"12","article-title":"Vitamin D deficiency and outcome of COVID-19 patients","author":"Radujkovic","year":"2020","journal-title":"Nutrients"},{"issue":"11","key":"10.1016\/j.ejca.2022.11.030_bib108","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1001\/jama.2020.26848","article-title":"Effect of a single high dose of vitamin D3 on hospital length of stay in patients with moderate to severe COVID-19: a randomized clinical trial","volume":"325","author":"Murai","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.ejca.2022.11.030_bib109","article-title":"Vitamin D supplementation for the treatment of COVID-19: a living systematic review","volume":"5","author":"Stroehlein","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ejca.2022.11.030_bib110","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.thromres.2020.04.024","article-title":"Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy","volume":"191","author":"Lodigiani","year":"2020","journal-title":"Thromb Res."},{"issue":"16","key":"10.1016\/j.ejca.2022.11.030_bib111","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1016\/j.jacc.2020.08.041","article-title":"Anticoagulation, bleeding, mortality, and pathology in hospitalized patients with COVID-19","volume":"76","author":"Nadkarni","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"10291","key":"10.1016\/j.ejca.2022.11.030_bib112","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1016\/S0140-6736(21)01203-4","article-title":"Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial","volume":"397","author":"Lopes","year":"2021","journal-title":"Lancet"},{"issue":"16","key":"10.1016\/j.ejca.2022.11.030_bib113","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1001\/jama.2021.4152","volume":"325","author":"Investigators","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.ejca.2022.11.030_bib114","article-title":"Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with COVID-19 admitted to hospital: RAPID randomised clinical trial","volume":"375","author":"Sholzberg","year":"2021","journal-title":"BMJ"},{"issue":"9","key":"10.1016\/j.ejca.2022.11.030_bib115","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1056\/NEJMoa2105911","article-title":"Therapeutic anticoagulation with heparin in noncritically ill patients with COVID-19","volume":"385","author":"Investigators","year":"2021","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.ejca.2022.11.030_bib116","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1111\/jth.15450","article-title":"Standard prophylactic versus intermediate dose enoxaparin in adults with severe COVID-19: a multi-center, open-label, randomized controlled trial","volume":"19","author":"Perepu","year":"2021","journal-title":"J Thromb Haemostasis"},{"issue":"9","key":"10.1016\/j.ejca.2022.11.030_bib117","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1056\/NEJMoa2103417","article-title":"Therapeutic anticoagulation with heparin in critically ill patients with COVID-19","volume":"385","author":"Investigators","year":"2021","journal-title":"N Engl J Med"},{"issue":"10319","key":"10.1016\/j.ejca.2022.11.030_bib118","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S0140-6736(21)02392-8","article-title":"Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial","volume":"399","author":"Ramacciotti","year":"2022","journal-title":"Lancet"},{"issue":"10320","key":"10.1016\/j.ejca.2022.11.030_bib119","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(21)01825-0","article-title":"Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial","volume":"399","author":"Group RC","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2022.11.030_bib120","article-title":"The effect of neutropenia and filgrastim (G-CSF) in cancer patients with COVID-19 infection","volume":"2020","author":"Morjaria","year":"2020","journal-title":"medRxiv"},{"issue":"4","key":"10.1016\/j.ejca.2022.11.030_bib121","doi-asserted-by":"crossref","first-page":"e102","DOI":"10.1016\/S1473-3099(21)00703-9","article-title":"Condition WHOCCDWGoP-C-. A clinical case definition of post-COVID-19 condition by a Delphi consensus","volume":"22","author":"Soriano","year":"2022","journal-title":"Lancet Infect Dis"},{"issue":"12","key":"10.1016\/j.ejca.2022.11.030_bib122","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1016\/S1470-2045(21)00573-8","article-title":"Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the onCovid retrospective, multicentre registry study","volume":"22","author":"Pinato","year":"2021","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.ejca.2022.11.030_bib123","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1002\/iub.2536","article-title":"One-year mortality and consequences of COVID-19 in cancer patients: a cohort study","volume":"73","author":"Chai","year":"2021","journal-title":"IUBMB Life"},{"issue":"11","key":"10.1016\/j.ejca.2022.11.030_bib124","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1007\/s00277-021-04656-z","article-title":"Clinical characteristics and outcomes of patients with haematologic malignancies and COVID-19 suggest that prolonged SARS-CoV-2 carriage is an important issue","volume":"100","author":"Arcani","year":"2021","journal-title":"Ann Hematol"},{"issue":"1","key":"10.1016\/j.ejca.2022.11.030_bib125","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1158\/2159-8290.CD-21-1033","article-title":"Prolonged SARS-CoV-2 infection in patients with lymphoid malignancies","volume":"12","author":"Lee","year":"2022","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ejca.2022.11.030_bib126","doi-asserted-by":"crossref","first-page":"110538","DOI":"10.1016\/j.mehy.2021.110538","article-title":"Persistent SARS-2 infections contribute to long COVID-19","volume":"149","author":"Jacobs","year":"2021","journal-title":"Med Hypotheses"},{"issue":"12","key":"10.1016\/j.ejca.2022.11.030_bib127","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1093\/qjmed\/hcab297","article-title":"Risk factors and incidence of long-COVID syndrome in hospitalized patients: does remdesivir have a protective effect?","volume":"114","author":"Boglione","year":"2022","journal-title":"QJM"},{"key":"10.1016\/j.ejca.2022.11.030_bib128","doi-asserted-by":"crossref","first-page":"758405","DOI":"10.3389\/fmed.2021.758405","article-title":"Short-course of methylprednisolone improves respiratory functional parameters after 120 Days in hospitalized COVID-19 patients (metcovid trial): a randomized clinical trial","volume":"8","author":"Barros","year":"2021","journal-title":"Front Med (Lausanne)"},{"issue":"5","key":"10.1016\/j.ejca.2022.11.030_bib129","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1513\/AnnalsATS.202008-1002OC","article-title":"Persistent post-COVID-19 interstitial lung disease. An observational study of corticosteroid treatment","volume":"18","author":"Myall","year":"2021","journal-title":"Ann Am Thorac Soc."},{"issue":"1","key":"10.1016\/j.ejca.2022.11.030_bib130","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/jmv.27296","article-title":"Corticosteroids for COVID-19 symptoms and quality of life at 1 year from admission","volume":"94","author":"Catalan","year":"2022","journal-title":"J Med Virol"},{"issue":"7","key":"10.1016\/j.ejca.2022.11.030_bib131","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1001\/jama.2022.11691","article-title":"Association between BNT162b2 vaccination and long COVID after infections not requiring hospitalization in health care workers","volume":"328","author":"Azzolini","year":"2022","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.ejca.2022.11.030_bib132","first-page":"13","article-title":"Feasibility of vitamin C in the treatment of post viral fatigue with focus on long COVID, based on a systematic review of IV vitamin C on fatigue","author":"Vollbracht","year":"2021","journal-title":"Nutrients"},{"key":"10.1016\/j.ejca.2022.11.030_bib133","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.clnesp.2021.08.031","article-title":"Observational study on the benefit of a nutritional supplement, supporting immune function and energy metabolism, on chronic fatigue associated with the SARS-CoV-2 post-infection progress","volume":"46","author":"Rossato","year":"2021","journal-title":"Clin Nutr ESPEN"},{"key":"10.1016\/j.ejca.2022.11.030_bib134","first-page":"103145","article-title":"Can l-carnitine reduce post-COVID-19 fatigue?","volume":"73","author":"Vaziri-Harami","year":"2022","journal-title":"Ann Med Surg (Lond)"},{"issue":"1","key":"10.1016\/j.ejca.2022.11.030_bib135","first-page":"21","article-title":"Efficacy of corticosteroid therapy in the treatment of long- lasting olfactory disorders in COVID-19 patients","volume":"59","author":"Vaira","year":"2021","journal-title":"Rhinology"},{"issue":"6","key":"10.1016\/j.ejca.2022.11.030_bib136","doi-asserted-by":"crossref","first-page":"e629","DOI":"10.7861\/clinmed.2021-0462","article-title":"Hyperbaric oxygen therapy for the treatment of long COVID: early evaluation of a highly promising intervention","volume":"21","author":"Robbins","year":"2021","journal-title":"Clin Med (Lond)"},{"key":"10.1016\/j.ejca.2022.11.030_bib137","first-page":"1","article-title":"Multidisciplinary outpatient rehabilitation of physical and neurological sequelae and persistent symptoms of COVID-19: a prospective, observational cohort study","author":"Albu","year":"2021","journal-title":"Disabil Rehabil"},{"issue":"7","key":"10.1016\/j.ejca.2022.11.030_bib138","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.nrl.2021.03.008","article-title":"Neuropsychological rehabilitation program for patients with post-COVID-19 syndrome: a clinical experience","volume":"36","author":"Garcia-Molina","year":"2021","journal-title":"Neurologia"},{"issue":"44","key":"10.1016\/j.ejca.2022.11.030_bib139","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.15585\/mmwr.mm7044e3","article-title":"Effectiveness of 2-dose vaccination with mRNA COVID-19 vaccines against COVID-19-associated hospitalizations among immunocompromised adults - nine states, January-September 2021","volume":"70","author":"Embi","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"11","key":"10.1016\/j.ejca.2022.11.030_bib140","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1016\/j.annonc.2021.07.012","article-title":"Reduced SARS-CoV-2 infection and death after two doses of COVID-19 vaccines in a series of 1503 cancer patients","volume":"32","author":"Heudel","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2022.11.030_bib141","article-title":"Efficacy of booster doses in augmenting waning immune responses to COVID-19 vaccine in patients with cancer","author":"Shapiro","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejca.2022.11.030_bib142","article-title":"Assessment of response to a third dose of the SARS-CoV-2 BNT162b2 mRNA vaccine in patients with solid tumors undergoing active treatment","author":"Rottenberg","year":"2021","journal-title":"JAMA Oncol"},{"issue":"11","key":"10.1016\/j.ejca.2022.11.030_bib143","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1038\/s41591-021-01542-z","article-title":"Immune responses to two and three doses of the BNT162b2 mRNA vaccine in adults with solid tumors","volume":"27","author":"Shroff","year":"2021","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.ejca.2022.11.030_bib144","doi-asserted-by":"crossref","first-page":"100274","DOI":"10.1016\/j.esmoop.2021.100274","article-title":"Reduced humoral immune response after BNT162b2 coronavirus disease 2019 messenger RNA vaccination in cancer patients under antineoplastic treatment","volume":"6","author":"Peeters","year":"2021","journal-title":"ESMO Open"},{"issue":"8","key":"10.1016\/j.ejca.2022.11.030_bib145","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.ccell.2021.06.002","article-title":"Seroconversion rates following COVID-19 vaccination among patients with cancer","volume":"39","author":"Thakkar","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejca.2022.11.030_bib146","article-title":"Functional antibody and T-cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study","author":"Fendler","year":"2021","journal-title":"Res Sq"},{"issue":"12","key":"10.1016\/j.ejca.2022.11.030_bib147","doi-asserted-by":"crossref","first-page":"3534","DOI":"10.1038\/s41375-021-01354-7","article-title":"Response to mRNA vaccination for COVID-19 among patients with multiple myeloma","volume":"35","author":"Stampfer","year":"2021","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.ejca.2022.11.030_bib148","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/S1473-3099(21)00751-9","article-title":"Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial","volume":"22","author":"Group AC-TfIwC-S","year":"2022","journal-title":"Lancet Infect Dis"},{"issue":"12","key":"10.1016\/j.ejca.2022.11.030_bib149","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1001\/jamainternmed.2021.6203","article-title":"Efficacy and safety of therapeutic-dose heparin vs standard prophylactic or intermediate-dose heparins for thromboprophylaxis in high-risk hospitalized patients with COVID-19: the HEP-COVID randomized clinical trial","volume":"181","author":"Spyropoulos","year":"2021","journal-title":"JAMA Intern Med"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804922017804?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804922017804?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:40:23Z","timestamp":1760733623000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804922017804"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":149,"alternative-id":["S0959804922017804"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2022.11.030","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"AGIHO guideline on evidence-based management of COVID-19 in cancer patients: 2022 update on vaccination, pharmacological prophylaxis and therapy in light of the omicron variants","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2022.11.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2020.09.009","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}